FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247248444> ?p ?o ?g. }

• W2247248444 abstract "15062 Background: The survival of advanced gastric cancer remains poor, while no chemotherapy regimen was recognized standard. Oxaliplatin and Capecitabine (Xeloda) have demonstrated promising antitumor efficacy in advanced colorectal cancer. The present study was conducted to further evaluate the efficacy and safety of XELOX (Oxaliplatin and Xeloda) regimen in gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer were enrolled into this study. They all receive the XELOX regimens (Oxaliplatin 130mg/ m2 intravenously in 2 hours on day 1 followed by oral capecitabine 1000mg/ m2 twice daily for 14 days every 3 weeks).We evaluated the response every 2 cycles. Results: The median age of the total enrolled 45 patients was 55 years (range, 22–82 years), including 32 male and 13 female. They received a median of 5 cycles (range, 2–8 cycles) of XELOX. 21 of 45 patients (46.7%) achieved an objective response, 1 patient (2.2%) had completed response. 17 patients (37.8%) experienced stable disease. Median time to tumor progression (TTP) and median overall survival were not available yet due to the further follow-up needed. Most toxicity events were mild to moderate in XELOX regimen, with grade 3/4 neutropenia of 8.9 %, thrombocytopenia of 6.7%, anemia of 11.1%, hand-foot syndrome of 6.7 % and diarrhea of 6.7 %. Grade 3 neuropathy was 4.4%. The patients with advanced gastric cancer had a good tolerance to this chemotherapy. Conclusions: XELOX is a highly effective first-line treatment for unrsectable and metastatic gastric cancer. The response rates in this trial seems to be similar to those observed with FU/leucovorin/oxaliplatin combinations. XELOX is tolerable well in the treatment of advanced gastric cancer. No significant financial relationships to disclose." @default.
• W2247248444 created "2016-06-24" @default.
• W2247248444 creator A5001281697 @default.
• W2247248444 creator A5001768900 @default.
• W2247248444 creator A5006423482 @default.
• W2247248444 creator A5011804054 @default.
• W2247248444 creator A5019904756 @default.
• W2247248444 creator A5043334299 @default.
• W2247248444 creator A5055026440 @default.
• W2247248444 creator A5068044246 @default.
• W2247248444 creator A5070360488 @default.
• W2247248444 creator A5073545540 @default.
• W2247248444 creator A5091295838 @default.
• W2247248444 date "2007-06-20" @default.
• W2247248444 modified "2023-09-26" @default.
• W2247248444 title "Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer" @default.
• W2247248444 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15062" @default.
• W2247248444 hasPublicationYear "2007" @default.
• W2247248444 type Work @default.
• W2247248444 sameAs 2247248444 @default.
• W2247248444 citedByCount "1" @default.
• W2247248444 crossrefType "journal-article" @default.
• W2247248444 hasAuthorship W2247248444A5001281697 @default.
• W2247248444 hasAuthorship W2247248444A5001768900 @default.
• W2247248444 hasAuthorship W2247248444A5006423482 @default.
• W2247248444 hasAuthorship W2247248444A5011804054 @default.
• W2247248444 hasAuthorship W2247248444A5019904756 @default.
• W2247248444 hasAuthorship W2247248444A5043334299 @default.
• W2247248444 hasAuthorship W2247248444A5055026440 @default.
• W2247248444 hasAuthorship W2247248444A5068044246 @default.
• W2247248444 hasAuthorship W2247248444A5070360488 @default.
• W2247248444 hasAuthorship W2247248444A5073545540 @default.
• W2247248444 hasAuthorship W2247248444A5091295838 @default.
• W2247248444 hasConcept C121608353 @default.
• W2247248444 hasConcept C126322002 @default.
• W2247248444 hasConcept C143998085 @default.
• W2247248444 hasConcept C2777909004 @default.
• W2247248444 hasConcept C31760486 @default.
• W2247248444 hasConcept C526805850 @default.
• W2247248444 hasConcept C535046627 @default.
• W2247248444 hasConcept C71924100 @default.
• W2247248444 hasConceptScore W2247248444C121608353 @default.
• W2247248444 hasConceptScore W2247248444C126322002 @default.
• W2247248444 hasConceptScore W2247248444C143998085 @default.
• W2247248444 hasConceptScore W2247248444C2777909004 @default.
• W2247248444 hasConceptScore W2247248444C31760486 @default.
• W2247248444 hasConceptScore W2247248444C526805850 @default.
• W2247248444 hasConceptScore W2247248444C535046627 @default.
• W2247248444 hasConceptScore W2247248444C71924100 @default.
• W2247248444 hasLocation W22472484441 @default.
• W2247248444 hasOpenAccess W2247248444 @default.
• W2247248444 hasPrimaryLocation W22472484441 @default.
• W2247248444 hasRelatedWork W2007304396 @default.
• W2247248444 hasRelatedWork W2024881577 @default.
• W2247248444 hasRelatedWork W2037421249 @default.
• W2247248444 hasRelatedWork W2100620304 @default.
• W2247248444 hasRelatedWork W2303669053 @default.
• W2247248444 hasRelatedWork W2374642528 @default.
• W2247248444 hasRelatedWork W2473757312 @default.
• W2247248444 hasRelatedWork W2586369559 @default.
• W2247248444 hasRelatedWork W3030947182 @default.
• W2247248444 hasRelatedWork W2183282679 @default.
• W2247248444 isParatext "false" @default.
• W2247248444 isRetracted "false" @default.
• W2247248444 magId "2247248444" @default.
• W2247248444 workType "article" @default.